






A retrospective study based on the EBMT registry to address the outcomes of *FLT3*-ITD AML in patients with an age equal or over 60-year old undergoing allogeneic stem cell transplantation




- One of the most frequent mutations in acute myeloid leukemia (AML)
-  High risk of relapse and worse survival
- Standard indication for allogeneic stem cell transplantation

 **291** ≥ 60 year-old patients harboring *FLT3*-ITD AML

 **82%** Reduced intensity conditioning

 **55%** Unrelated donors

	1 st remission	2 nd remission	Active disease
 (n)	212 (p<0.005)	37 (p<0.005)	42 (p<0.005)
2-year LFS	56%	22%	10%

Conclusions

- Stem cell transplantation in early disease phase for eligible patient with *FLT3*-ITD AML
- Sibling donors or fully matched unrelated donors are the best donors even in elderly population